sufentanil citrate

Modify Date: 2024-01-03 09:04:01

sufentanil citrate structure	Common Name	sufentanil citrate
	CAS Number	60561-17-3	Molecular Weight	578.67400
	Density	N/A	Boiling Point	493.1ºC at 760 mmHg
	Molecular Formula	C₂₈H₃₈N₂O₉S	Melting Point	96.6ºC
	MSDS	Chinese USA	Flash Point	252ºC
	Symbol	GHS02, GHS06, GHS08	Signal Word	Danger

Name	2-hydroxypropane-1,2,3-tricarboxylic acid,N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
Synonym	More Synonyms

Boiling Point	493.1ºC at 760 mmHg
Melting Point	96.6ºC
Molecular Formula	C₂₈H₃₈N₂O₉S
Molecular Weight	578.67400
Flash Point	252ºC
Exact Mass	578.23000
PSA	193.15000
LogP	2.90420
Appearance of Characters	white to beige
Storage condition	-20°C Freezer
Water Solubility	H2O: soluble1mg/mL, clear

sufentanil citrate MSDS(Chinese)

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UE5295000

CHEMICAL NAME :: Propionanilide, N-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperid yl)-, citrate

CAS REGISTRY NUMBER :: 60561-17-3

LAST UPDATED :: 199009

DATA ITEMS CITED :: 9

MOLECULAR FORMULA :: C22-H30-N2-O2-S.C6-H8-O7

MOLECULAR WEIGHT :: 578.74

WISWESSER LINE NOTATION :: T6NTJ DNR&V2 D1O1 A2- BT5SJ &QV1U1VQ -T

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 1200 ng/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: AACRAT Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.36- 1957- Volume(issue)/page/year: 66,91,1987

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 606 ng/kg/5M-C

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: AACRAT Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.36- 1957- Volume(issue)/page/year: 66,91,1987

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 23 ug/kg/10M-C

TOXIC EFFECTS :: Vascular - BP lowering not characterized in autonomic section

REFERENCE :: AACRAT Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.36- 1957- Volume(issue)/page/year: 65,703,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 2777 ng/kg/3M-C

TOXIC EFFECTS :: Vascular - BP lowering not characterized in autonomic section

REFERENCE :: AACRAT Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.36- 1957- Volume(issue)/page/year: 65,703,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraspinal

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 1 ug/kg/20H-I

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: ANASAB Anaesthesia. (Academic Press Inc. Ltd., 24-28 Oval Rd., London NW1 7DX, UK) V.1- 1946- Volume(issue)/page/year: 42,665,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 17900 ug/kg

TOXIC EFFECTS :: Behavioral - analgesia

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1548,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 18700 ug/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1551,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 14100 ug/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1551,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 11800 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 21,210,1985

Symbol	GHS02, GHS06, GHS08
Signal Word	Danger
Hazard Statements	H225-H301 + H311 + H331-H370
Precautionary Statements	P210-P260-P280-P301 + P310-P311
Hazard Codes	T+,T,F
Risk Phrases	26/27/28-39/23/24/25-23/24/25-11
Safety Phrases	26-27-28-36/37/39-45-36/37-16-7
RIDADR	UN 3249
Packaging Group	III
Hazard Class	6.1(b)

sufentanil

CAS#:56030-54-7

Citric Acid

CAS#:77-92-9

~55%

sufentanil citrate

CAS#:60561-17-3

Literature: AUSPEX PHARMACEUTICALS, INC. Patent: US2010/16365 A1, 2010 ; Location in patent: Page/Page column 27 ; US 20100016365 A1

Precursor 2
CAS#:56030-54-7 sufentanil CAS#:77-92-9 Citric Acid
DownStream 0

Sufentanil citrate: a new opioid analgesic for use in anesthesia.

Pharmacotherapy 4(1) , 11-9, (1984)

Sufentanil citrate is a potent analogue of fentanyl that has been evaluated primarily for use in opioid anesthesia. It is a pure mu receptor agonist and produces the typical spectrum of opioid effects...

Criteria for use of fentanyl citrate, sufentanil citrate, and alfentanil hydrochloride.

Clin. Pharm. 10(8) , 635-7, (1991)

Influence of intensive care treatment on the protein binding of sufentanil and hydromorphone during pain therapy in postoperative cardiac surgery patients.

Br. J. Anaesth. 113(4) , 677-87, (2014)

Our objective was to evaluate the effect of intensive care treatment on the protein binding of sufentanil and hydromorphone in cardiac surgery patients during postoperative analgesia using a target-co...

EINECS 262-295-4

N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)-4-piperidyl]-N-phenylpropanamide citrate

UNII-S9ZFX8403R

N-(4-(methoxymethyl)-1-(2-(thiophen-2-yl)ethyl)piperidin-4-yl)-N-phenylpropionamide citrate

Sufentanyl citrate

sufentanil citrate

Sufenta

N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl}-N-phenylpropionamide citrate

N-[4-(methoxymethy)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide 2-hydroxy-1,2,3-propanetricarboxylate

Fentatienil

sufentanil cytrate

sufentanil citrate

Names

Chemical & Physical Properties

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

Safety Information

Synthetic Route

Precursor & DownStream

Articles30

Synonyms